Internal Medicine, Hematology & Oncology · Glendale, CA
NPI
1730262122
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1505 Wilson Terrace, Suite 340
Glendale, CA, 91206
Phone (818) 543-7574
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
248,423 services
Medicare patients, 2024
805
Average age 77
Drug cost, 2024
$11.3M
2,733 prescriptions
Company payments, 2025
$542
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mihran Shirinian was code J9271 (injection, pembrolizumab, 1 mg), 40,595 times for 29 patients. In total Mihran Shirinian billed 248,423 services in 90 codes, and Medicare paid $1.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-08-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 40,595 | 29 | $7.91 | $321K |
| J1756 Injection, iron sucrose, 1 mg | Office | 29,900 | 49 | $0.18 | $5,347 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 22,400 | 15 | $0.06 | $1,239 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 16,644 | 80 | $0.07 | $1,228 |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 16,500 | 16 | $0.88 | $14K |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 15,000 | 19 | $0.22 | $3,259 |
| J9035 Injection, bevacizumab, 10 mg | Office | 10,525 | 15 | $0.81 | $8,551 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,436 | 51 | $0.09 | $400 |
| 36415 Venipuncture Blood Collection | Office | 4,086 | 707 | $8.65 | $35K |
| 85025 Blood Count | Office | 4,062 | 706 | $7.61 | $31K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,560 | 32 | $6.37 | $16K |
| 99213 Office E&M - Established | Office | 2,132 | 206 | $69.76 | $149K |
| 99214 Office E&M - Established | Office | 1,798 | 623 | $90.25 | $162K |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 1,663 | 22 | $3.57 | $5,939 |
| J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 1,629 | 139 | $1.03 | $1,681 |
By year: 2022 $961K for 181,304 services; 2023 $1.4M for 203,185 services; 2024 $1.5M for 248,423 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 4,086 | 707 | $8.65 | $35K |
| 85025 Blood Count | 4,062 | 706 | $7.61 | $31K |
Medicare prescription drug claims, 2024
In 2024, the drug Mihran Shirinian prescribed most often to Medicare patients was Anastrozole, with 244 prescriptions and refills. In total Mihran Shirinian wrote 2,733 Medicare prescriptions that cost $11.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 244 | 386 | 43 | $2,185 |
| Keytruda Pembrolizumab | 199 | 199 | 27 | $2.1M |
| Avastin Bevacizumab | 156 | 156 | 15 | $938K |
| Ondansetron Odt Ondansetron | 140 | 148 | 47 | $3,210 |
| Aprepitant Generic | 125 | 125 | 25 | $49K |
| Hydroxyurea Generic | 122 | 159 | 19 | $1,430 |
| Letrozole Generic | 121 | 165 | 20 | $1,309 |
| Alendronate Sodium Generic | 115 | 152 | 24 | $427 |
| Eliquis Apixaban | 82 | 94 | 11 | $56K |
| Dexamethasone Generic | 73 | 74 | 18 | $570 |
| Lynparza Olaparib | 68 | 72 | Under 11 | $961K |
| Pantoprazole Sodium Generic | 45 | 49 | 14 | $133 |
| Verzenio Abemaciclib | 45 | 45 | Under 11 | $679K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 43 | 43 | Under 11 | $37.34 |
| Xtandi Enzalutamide | 40 | 40 | Under 11 | $547K |
Brand drugs: - claims; generic drugs: 1,552 claims; opioid claims: 62.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mihran Shirinian $542 ($542 in general payments such as food, travel and fees) from 13 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $150.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 3 | $150 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 2 | $81.14 |
| Abbvie Inc. ABBV | 2 | $59.88 |
| Astellas Pharma US Inc 4503.T | 2 | $51.34 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $43.04 |
| Deciphera Pharmaceuticals Inc. | 1 | $33.58 |
| Caris MPI, Inc. | 1 | $31.81 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $28.95 |
| Adaptive Biotechnologies Corporation ADPT | 1 | $24.63 |
| Pfizer Inc. PFE | 3 | $23.7 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.